Antipsychotic Effects on Brain Function in Schizophrenia

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder

In brief

The purpose of the study is to determine whether two commonly-prescribed antipsychotic medications (aripiprazole and risperidone) have different effects on brain function and cognition in schizophrenia patients.

Key facts

Study ID

NCT01913327

Run by

University of California, San Francisco

People needed

4

Starts

2013-04-01

Expected to finish

2017-01-01

Last updated by the study team

2020-04-20

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• less than 40 years old;
• currently meet criteria for schizophrenia, schizophreniform disorder or schizoaffective disorder from the DSM-IV-TR;
• require new or changed treatment with antipsychotic medication.

You may not qualify if…

• older than 40 years;
• in current antipsychotic treatment that is satisfactory;
• treatment-refractory psychosis;
• active substance-related disorder;
• clinically-unstable (e.g. acute symptoms requiring emergent or acute-care, including acute suicide risk);
• neurological illness or poorly-controlled medical illness;
• currently taking medications for serious medical illness which have significant interactions with modafinil;
• active pregnancy;
• intelligence less than 70 (on standard test);
• contraindications for fMRI (e.g. claustrophobia, metal foreign bodies, etc.);
• uncorrectable visual acuity impairment.

Where it is running

• University of California — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.